Experts Predict SLYG Will Reach $108
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Should l Buy UFPT?
Source: NASDAQ.COM
ETF Analysis: The SPDR S&P 600 Small Cap Growth ETF (SLYG) has an implied analyst target price of $107.87, indicating a potential upside of 18.06% from its current trading price of $91.36.
Notable Holdings: Key underlying holdings with significant upside include UFP Technologies Inc. (UFPT), Middlesex Water Co. (MSEX), and Progyny Inc. (PGNY), with expected price increases of 49.86%, 21.19%, and 21.05% respectively.
Analyst Target Justification: There are questions regarding whether analysts' target prices are justified or overly optimistic, considering recent company and industry developments.
Investor Research Needed: Investors are encouraged to conduct further research to determine the validity of these analyst targets and their implications for future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UFPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UFPT
About UFPT
UFP Technologies, Inc. is a designer and custom manufacturer of solutions for medical devices, sterile packaging, and other engineered custom products. The Company’s single-use and single-patient devices and components are used in a range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Its manufacturing operations consist primarily of cutting, routing, compression and injection molding, vacuum-forming, micro-molding, thermoforming, laminating, radio frequency and impulse welding, and assembling. It also engineers components for automotive use in interior trim and structural applications. These components are produced using a compression molding process to create functional composites consisting of various materials such as polypropylene/fiberglass panels, nonwovens, and fabrics. It also develops and manufactures precision thermo-formed and heat-sealed polymer components.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
UFP Technologies Shares Enter Oversold Territory
- Oversold Signal: UFP Technologies Inc. has an RSI of 29.9, indicating that the stock may be nearing a bottom after significant selling, prompting investors to consider buying opportunities.
- Price Fluctuation: The stock hit a low of $207.475, with the current trading price at $210.58, showing some recovery from the 52-week low of $178.26, reflecting cautious optimism about its future performance.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 46.1, UFP's oversold condition may attract investors looking for a rebound, highlighting a divergence in market sentiment.
- Historical Performance: UFP's 52-week high is $274.93, and the current price still has a significant gap from this peak, indicating potential rebound space and investment value.
See More
UFP Technologies Reports Q4 2025 Earnings with Strong Growth and Strategic Developments
- Significant Sales Growth: UFP Technologies reported full-year sales of $602.8 million for 2025, reflecting a 19.5% increase, with CEO R. Bailly highlighting this milestone as nearly tripling revenue since 2021, indicating robust market performance.
- Operational Efficiency Gains: Despite incurring $6.3 million in labor inefficiencies at the AJR facility, the company achieved a 15.4% increase in EPS for 2025, demonstrating substantial progress in onboarding and training new labor, with expectations for further improvements ahead.
- Strategic Expansion Plans: The completion of a fifth building in the Dominican Republic and plans for a sixth to enhance robotic surgery capacity were underscored, with the CEO noting that a contract extension with the largest customer is projected to materially increase volumes in the coming years.
- Strong Financial Performance: Cash from operations reached $92 million, with approximately $53.9 million in debt repayment, resulting in a leverage ratio of 1.1x, while gross margin decreased to 28.2% due to additional labor costs, yet adjusted operating margin remained within the target range at 17.1%.
See More
UFP Tech (UFPT) Q4 2025 Earnings Call Transcript
See More
UFP Technologies Reports Quarterly Earnings Beat
- Earnings Beat: UFP Technologies reported quarterly earnings of $2.44 per share, surpassing the Zacks consensus estimate of $2.26, indicating stable profitability despite a slight decline from $2.46 a year ago.
- Revenue Miss: The company posted revenues of $148.92 million for the quarter, falling short of the Zacks consensus estimate of $150.5 million, although this reflects a 3.9% year-over-year increase, suggesting ongoing market demand amid challenges.
- Strong Stock Performance: UFP shares have risen approximately 8.9% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500, highlighting the company's relative strength in the market and attracting investor interest.
- Cautious Outlook: With current EPS estimates at $2.55 and revenue expectations at $156.63 million, management's commentary will significantly influence short-term stock movements, prompting investors to closely monitor future earnings estimate revisions.
See More
UFP Technologies Q4 Earnings Beat Expectations
- Earnings Beat: UFP Technologies reported a Q4 non-GAAP EPS of $2.44, exceeding expectations by $0.21, indicating a strong profitability trend despite revenue challenges.
- Revenue Growth Lags: The company achieved Q4 revenue of $148.9 million, a 3.3% year-over-year increase, yet it fell short of market expectations by $0.17 million, highlighting competitive pressures and growth challenges.
- Adjusted EBITDA Decline: Adjusted EBITDA for Q4 decreased to $28.3 million from $30.4 million in Q4 2024, suggesting challenges in cost management and operational efficiency.
- Annual Improvement: For the year ending December 31, 2025, adjusted EBITDA rose to $121.1 million from $107.3 million in 2024, indicating a positive trend in overall business operations.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
UFP Technologies Shares Enter Oversold Territory
- Oversold Signal: UFP Technologies Inc. has an RSI of 29.9, indicating that the stock may be nearing a bottom after significant selling, prompting investors to consider buying opportunities.
- Price Fluctuation: The stock hit a low of $207.475, with the current trading price at $210.58, showing some recovery from the 52-week low of $178.26, reflecting cautious optimism about its future performance.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 46.1, UFP's oversold condition may attract investors looking for a rebound, highlighting a divergence in market sentiment.
- Historical Performance: UFP's 52-week high is $274.93, and the current price still has a significant gap from this peak, indicating potential rebound space and investment value.
See More
UFP Technologies Reports Q4 2025 Earnings with Strong Growth and Strategic Developments
- Significant Sales Growth: UFP Technologies reported full-year sales of $602.8 million for 2025, reflecting a 19.5% increase, with CEO R. Bailly highlighting this milestone as nearly tripling revenue since 2021, indicating robust market performance.
- Operational Efficiency Gains: Despite incurring $6.3 million in labor inefficiencies at the AJR facility, the company achieved a 15.4% increase in EPS for 2025, demonstrating substantial progress in onboarding and training new labor, with expectations for further improvements ahead.
- Strategic Expansion Plans: The completion of a fifth building in the Dominican Republic and plans for a sixth to enhance robotic surgery capacity were underscored, with the CEO noting that a contract extension with the largest customer is projected to materially increase volumes in the coming years.
- Strong Financial Performance: Cash from operations reached $92 million, with approximately $53.9 million in debt repayment, resulting in a leverage ratio of 1.1x, while gross margin decreased to 28.2% due to additional labor costs, yet adjusted operating margin remained within the target range at 17.1%.
See More
UFP Tech (UFPT) Q4 2025 Earnings Call Transcript
See More
UFP Technologies Reports Quarterly Earnings Beat
- Earnings Beat: UFP Technologies reported quarterly earnings of $2.44 per share, surpassing the Zacks consensus estimate of $2.26, indicating stable profitability despite a slight decline from $2.46 a year ago.
- Revenue Miss: The company posted revenues of $148.92 million for the quarter, falling short of the Zacks consensus estimate of $150.5 million, although this reflects a 3.9% year-over-year increase, suggesting ongoing market demand amid challenges.
- Strong Stock Performance: UFP shares have risen approximately 8.9% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500, highlighting the company's relative strength in the market and attracting investor interest.
- Cautious Outlook: With current EPS estimates at $2.55 and revenue expectations at $156.63 million, management's commentary will significantly influence short-term stock movements, prompting investors to closely monitor future earnings estimate revisions.
See More
UFP Technologies Q4 Earnings Beat Expectations
- Earnings Beat: UFP Technologies reported a Q4 non-GAAP EPS of $2.44, exceeding expectations by $0.21, indicating a strong profitability trend despite revenue challenges.
- Revenue Growth Lags: The company achieved Q4 revenue of $148.9 million, a 3.3% year-over-year increase, yet it fell short of market expectations by $0.17 million, highlighting competitive pressures and growth challenges.
- Adjusted EBITDA Decline: Adjusted EBITDA for Q4 decreased to $28.3 million from $30.4 million in Q4 2024, suggesting challenges in cost management and operational efficiency.
- Annual Improvement: For the year ending December 31, 2025, adjusted EBITDA rose to $121.1 million from $107.3 million in 2024, indicating a positive trend in overall business operations.
See More
